{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:23:44Z","timestamp":1790245424652,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.leukres.2017.05.002","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T13:01:29Z","timestamp":1496235689000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia"],"prefix":"10.1016","volume":"60","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Courby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie Baker","family":"Brachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia D.","family":"Maltzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bajel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.05.002_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.05.002_bib0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2017.05.002_bib0015","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.2174\/092986712803251511","article-title":"Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib","volume":"19","author":"Mascarenhas","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.leukres.2017.05.002_bib0020","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larran","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2017.05.002_bib0025","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larran","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.002_bib0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2017.05.002_bib0035","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2017.05.002_bib0040","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.05.002_bib0045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2017.05.002_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2040620712461047","article-title":"Comprehensive review of JAK inhibitors in myeloproliferative neoplasms","volume":"4","author":"Sonbol","year":"2013","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.leukres.2017.05.002_bib0055","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.05.002_bib0060","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12185-015-1808-y","article-title":"The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis","volume":"102","author":"Qin","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2017.05.002_bib0065","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","article-title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable","volume":"143","author":"Kim","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2017.05.002_bib0070","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.05.002_bib0075","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.05.002_bib0080","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.05.002_bib0085","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2017.05.002_bib0090","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.05.002_bib0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bjh.12607","article-title":"Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation","volume":"164","author":"Hexner","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.05.002_bib0100","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.05.002_bib0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/asheducation-2014.1.277","article-title":"R.A. Mesa. Therapy for myeloproliferative neoplasms: when, which agent, and how","volume":"2014","author":"Geyer","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.leukres.2017.05.002_bib0110","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1\/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients","volume":"23","author":"Pardanani","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.05.002_bib0115","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2011.175","article-title":"The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells","volume":"25","author":"Monaghan","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.05.002_bib0120","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.002_bib0125","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.05.002_bib0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.2016.148924","article-title":"A phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis","volume":"102","author":"Gupta","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.05.002_bib0135","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.tps6641","article-title":"A randomized phase II, open label trial of orally administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea","volume":"30","author":"Tefferi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.05.002_bib0140","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2017.05.002_bib0145","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1182\/blood.V122.21.665.665","article-title":"Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET)","volume":"122","author":"Verstovsek","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.002_bib0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2017.05.002_bib0155","series-title":"Jakafi\u00ae (ruxolitinib) Tablets, for Oral Use. Prescribing Information","year":"2016"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T22:38:30Z","timestamp":1602196710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617304162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":31,"alternative-id":["S0145212617304162"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.05.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}